Global Markets Direct’s, ‘Urinary Incontinence – Pipeline Review, H1 2016’, provides an overview of the Urinary Incontinence pipeline landscape.
The report provides comprehensive information on the therapeutics under development for Urinary Incontinence, complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The report also covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases. Additionally, the report provides an overview of key players involved in therapeutic development for Urinary Incontinence and features dormant and discontinued projects.
Global Markets Direct’s report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from Global Markets Direct’s proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Drug profiles featured in the report undergoes periodic review following a stringent set of processes to ensure that all the profiles are updated with the latest set of information. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.
Request a sample of this report @ http://www.orbisresearch.com/contacts/request-sample/142045
The report helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage.
Note: Certain sections in the report may be removed or altered based on the availability and relevance of data.
– The report provides a snapshot of the global therapeutic landscape of Urinary Incontinence
– The report reviews pipeline therapeutics for Urinary Incontinence by companies and universities/research institutes based on information derived from company and industry-specific sources
– The report covers pipeline products based on various stages of development ranging from pre-registration till discovery and undisclosed stages
– The report features descriptive drug profiles for the pipeline products which includes, product description, descriptive MoA, R&D brief, licensing and collaboration details & other developmental activities
– The report reviews key players involved Urinary Incontinence therapeutics and enlists all their major and minor projects
– The report assesses Urinary Incontinence therapeutics based on drug target, mechanism of action (MoA), route of administration (RoA) and molecule type
– The report summarizes all the dormant and discontinued pipeline projects
– The report reviews latest news related to pipeline therapeutics for Urinary Incontinence
Purchase a copy of Urinary Incontinence-Pipeline Review, H1 2016 visit @ http://www.orbisresearch.com/contact/purchase/142045
Reasons to buy
– Gain strategically significant competitor information, analysis, and insights to formulate effective R&D strategies
– Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage
– Identify and understand important and diverse types of therapeutics under development for Urinary Incontinence
– Identify potential new clients or partners in the target demographic
– Develop strategic initiatives by understanding the focus areas of leading companies
– Plan mergers and acquisitions effectively by identifying key players and it’s most promising pipeline therapeutics
– Devise corrective measures for pipeline projects by understanding Urinary Incontinence pipeline depth and focus of Indication therapeutics
– Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope
– Modify the therapeutic portfolio by identifying discontinued projects and understanding the factors that drove them from pipeline
Astellas Pharma Inc.
Cook MyoSite Incorporated
FemmePharma Global Healthcare, Inc.
Innovacell Biotechnologie AG
Taiho Pharmaceutical Co., Ltd.
Some Points From Toc:
Table of Contents
Table of Contents 2
List of Tables 5
List of Figures 6
Global Markets Direct Report Coverage 7
Urinary Incontinence Overview 8
Therapeutics Development 9
Pipeline Products for Urinary Incontinence – Overview 9
Pipeline Products for Urinary Incontinence – Comparative Analysis 10
Urinary Incontinence – Therapeutics under Development by Companies 11
Urinary Incontinence – Therapeutics under Investigation by Universities/Institutes 12
Urinary Incontinence – Pipeline Products Glance 13
Late Stage Products 13
Clinical Stage Products 14
Early Stage Products 15
Urinary Incontinence – Products under Development by Companies 16
Urinary Incontinence – Products under Investigation by Universities/Institutes 17
Urinary Incontinence – Companies Involved in Therapeutics Development 18
Astellas Pharma Inc. 18
Cook MyoSite Incorporated 20